Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Early risk response to vasodilators and outcomes in interstitial lung disease associated pulmonary hypertension.

Respiratory investigation·2026

Same author

Neonatal Case of Fetal Pleural Effusion Caused by Cor Triatriatum Dexter with Postnatal Worsening of Superior Vena Cava Syndrome.

Pediatric cardiology·2026

Same author

Impact of Plasticizers on the Microbial Degradation of Polyhydroxybutyrate (PHB).

Toxics·2026

Same author

Incidence of RSV- and Influenza-Associated Hospitalizations With Community-Acquired Pneumonia and Other Acute Respiratory Infection Among Adults in Japan in 2022-2024: APSG-J2 Study.

Influenza and other respiratory viruses·2026

Same author

Diagnostic utility of quantitative interferon-gamma release assays in elderly patients with tuberculosis.

Microbiology spectrum·2026

Same author

Symptomatic Pulmonary Regurgitation Without Right Ventricular Enlargement Accompanied by Biventricular Diastolic Dysfunction in Repaired Tetralogy of Fallot and Related Diseases.

Circulation journal : official journal of the Japanese Circulation Society·2026

Search research articles

Related Experiment Video

Updated: Sep 16, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

First-Line Osimertinib for EGFR-Mutated Squamous Cell Lung Carcinoma: A Case Report.

Yugo Matsumura¹, Seiya Ichihara¹, Kaori Nii¹

¹Department of Respiratory Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.

Cancer Reports (Hoboken, N.J.)

|July 7, 2025

Summary

A rare case of squamous cell lung carcinoma with an epidermal growth factor receptor (EGFR) mutation showed a positive response to osimertinib treatment. This finding suggests osimertinib may be a viable option for this specific patient group.

Keywords:

EGFR mutation EGFR‐TKI L858R osimertinib squamous cell lung cancer

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Experiment Videos

Last Updated: Sep 16, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Area of Science:

Oncology
Genomics
Thoracic Surgery

Background:

Squamous cell lung carcinoma (SCLC) rarely harbors epidermal growth factor receptor (EGFR) mutations.
EGFR-tyrosine kinase inhibitors (TKIs) typically demonstrate limited efficacy in EGFR-mutated SCLC.
This case highlights a deviation from the general trend, presenting a responsive EGFR-mutated SCLC.

Observation:

A 75-year-old female presented with hemoptysis and back pain, diagnosed with stage IVA SCLC with adrenal metastasis.
Genomic analysis revealed an EGFR exon 21 L858R mutation in the primary tumor.
The tumor exhibited a high PD-L1 expression (95%).

Findings:

First-line treatment with osimertinib resulted in significant tumor shrinkage.
The therapeutic response was maintained for over 9 months.
This indicates a notable sensitivity to osimertinib in this rare SCLC subtype.

Implications:

Osimertinib demonstrates potential efficacy in a subset of EGFR-mutated SCLC patients.
This case expands the therapeutic considerations for SCLC beyond standard treatment protocols.
Further investigation into EGFR-mutated SCLC response to targeted therapies is warranted.